---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-138796"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T14:08:34.690837+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# AN2 Therapeutics posts updated investor presentation with no new material facts

## Summary
- Filed 8-K under Item 7.01 furnishing an updated investor presentation dated June 2025.
- No specific financial results, pipeline updates, or guidance changes disclosed in the filing.
- Presentation available on the 'Investors' section of the company's website.
- No material information beyond the routine investor update was provided.

## SEC filing metadata
- accession: 0001193125-25-138796
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312525138796/0001193125-25-138796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312525138796/d812980d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-138796
- JSON: https://secwatch.observer/filing/0001193125-25-138796.json
- Plain text: https://secwatch.observer/filing/0001193125-25-138796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.